Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015)

References

• Chen JW. Diabetes, metabolic syndrome and atherosclerosis threaten people’s health. The first national conference of basic and clinical topics of the metabolic syndrome; Jinan; 2004;1:2–4.
   Google Scholar
• Wang HR, Yu CJ. New progress in mechanism and treatment of atherosclerosis. J Capital Med Univ. 2010;6:828–833.
   Google Scholar
• Zhang LL. The progress in obstetrics and gynecology. Prog Obstet Gynecol. 2007;6:464–466.
   Google Scholar
• Shu QH, Zhang G. The advances in research of the correlation between free fatty acid and coronary atherosclerotic heart disease. Med Recapitulate. 2009;20:3110–3112.
   Google Scholar
• Sui SH, Bai J. The advances in research of adipocyte fatty acid binding proteins, metabolic disorders and atherosclerosis. J Jining Med Coll. 2011;2:139–141.
   Google Scholar
• Yang YZ. The research status of Chinese atherosclerosis pathology physiology. Chin J Arterioscler. 2004;4:481–489.
   Google Scholar
• Wang N, Xie ZJ, Li XY, et al. The relationship between atherosclerosis and the expression of free fatty acid in diabetic rats. Chin J Arterioscler. 2005;5:563–566.
   Google Scholar
• Gu DF, Reynolds K, Yang WJ, et al. The prevalence of metabolic syndrome in the general adult population aged 35–74 years in China. Chin J Diabetes. 2005;3:181–186.
   Google Scholar
• Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes and vascular diseases. Eur Heart J. 2008;29(24):2959–2971.
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NADPH oxidase in cultured vascular cells. Diabetes. 2000;49:1939–1945.
   PubMed Web of Science ®Google Scholar
• Quehenberger P, Bierhaus A, Fasching P, et al. Endothelin 1 transcription is controlled by nuclear factor-kappa B in AGE-stimulated cultured endothelial cells. Diabetes. 2000;49:1561–1570.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489–503.
   PubMed Web of Science ®Google Scholar
• Makowski L, Hotamisligil GS. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. NIH Public Access. 2005;5:543–548.
   Google Scholar
• Feng AJ, Chen DF. The research progress of fatty acid binding proteins. World Chin J Digestol. 2003;9:1457–1459.
   Google Scholar
• Roden M. Blocking fatty acids’ mystery tour: a therapy for metabolic syndrome. Cell Metab. 2007;6:89–91.
   PubMed Web of Science ®Google Scholar
• van Dongen MJP, Uppenberg J, Svensson S, et al. Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation. J Am Chem Soc. 2002;124:11874–11880.
   PubMed Web of Science ®Google Scholar
• Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr. 2008;28:73–95.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996;274:1377–1379.
   PubMed Web of Science ®Google Scholar
• Uysal KT, Scheja L, Wiesbrock SM, et al. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology. 2000;141(9):3388–3396.
   PubMed Web of Science ®Google Scholar
• Maeda K, Cao H, Kono K, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 2005;1:107–119.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Fucho R, Görgün CZ, et al. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest. 2008;7:2640–2650.
   Google Scholar
• Fu Y, Luo L, Luo N, et al. Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis. 2006;188:102–111.
   PubMed Web of Science ®Google Scholar
• Haunerland NH, Spener F. Properties and physiological significance of fatty acid binding proteins. Prog Lipid Res. 2004;43:328–349.
   PubMed Web of Science ®Google Scholar
• Yan GR, Zhang XD, Cai HY, et al. The potential target of diabetes an atherosclerosis-FABP4 (aP2). Biology. 2009;2:270–275.
   PubMed Web of Science ®Google Scholar
• Jin J. The advances in research of adipocyte fatty acid binding proteins and atherosclerosis. Chin Journey Atheroscler. 2009;4:327–330.
   Google Scholar
• Bristol-Myers Squibb Company; USA:2002. US2002/0091078A1.
   Google Scholar
• Bristol-Myers Squibb Company; USA:2003. WO03/043624A1.
   Google Scholar
• Bristol-Myers Squibb Company; USA:2003. US2003/0040516A1.
   Google Scholar
• Bristol-Myers Squibb Company; USA:2003. US6548529B1.
   Google Scholar
• Carlson LA. Nicotinic acid and inhibition of fat mobilizing lipolysis. Present status of effect on lipid metabolism. Drugs Lipid Metabol Atheroscler. 1978;109:225–238.
   Google Scholar
• Carlson LA, Fröberg SO, Nye ER, et al. Acute effects of nicotinic acid on plasma, liver, heart and muscle lipids. Acta Med Scand. 1996;5:571–580.
   Google Scholar
• Trustees of Tufts College; USA:2015. US8937063B2.
   Google Scholar
• Trustees of Tufts College; USA:2013. US8450316B2.
   Google Scholar
• Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99(6):S22–S31.
   Google Scholar
• Ohmori J, Sakamoto S, Kubota H, et al. 6-(1H-Imidazol-1-yl)-7-nitro-2,3-(1H, 4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AM PA 2 type of non- NMDA receptor. J Med Chem. 1994;37:467–475.
   PubMed Web of Science ®Google Scholar
• Sastry CVR, Jogbhukta M, Krishkan VSH, et al. Synthesis and biological activiaties of some 1,5-dihydro [1,2,4] ditriazolo [4,3-a:3ʹ,4ʹ-c] quinoxaline-1,6-diones. Ind J Chem. 1998;27:1110–1112.
   Google Scholar
• Wu Z, Ede NJ. Solid-phase synthesis of quinoxalines on SynPhase™ Lanterns. Tet Let. 2001;42:8115–8118.
   Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp; USA:2014. US8889683B2.
   Google Scholar
• Bagheri R, Qasim AN, Mehta NN, et al. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol. 2010;106:1118–1123.
   PubMed Web of Science ®Google Scholar
• Wang YX, Ai J, Wang Y, et al. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-Trisubstituted quinolines: identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anti-cancer agent. J Med Chem. 2011;54:2127–2142.
   PubMed Web of Science ®Google Scholar
• Xia LK, Idhayadhulla A, Lee YR, et al. Microwave-assisted synthesis of diverse pyrrolo[3,4-c]quinoline-1,3-diones and their antibacterial activities. ACS Com Sci. 2014;16:333–341.
   PubMed Web of Science ®Google Scholar
• Baba A, Kawamura N, Makino H, et al. Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect. J Med Chem. 1996;39:5176–5182.
   PubMed Web of Science ®Google Scholar
• Hoffmann-LA Roche Inc.; USA:2013. US2013/0116234A1.
   Google Scholar
• Hoffmann-LA Roche Inc.; USA:2014. US2014/029723A1.
   Google Scholar
• Lan H, Cheng CC, Kowalski TJ, et al. Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity. J Lipid Res. 2011;52:646–656.
   PubMed Web of Science ®Google Scholar
• Hoffmann-LA Rocheinc Inc.; USA:2014. WO2014/146995A1.
   Google Scholar
• Hoffmann-LA Roche Inc.; USA:2014. US2014/146994A1.
   Google Scholar
• Merck Sharp & Dohme Corp; USA:2014. US8815875B2.
   Google Scholar
• Merck Sharp & Dohme Corp; USA:2014. US8759357B2.
   Google Scholar
• Schering Corporation; USA:2012. US2012/0190696A1.
   Google Scholar
• Hoffmann-LA Roche Inc.; USA:2015. US2015/0183778A1.
   Google Scholar
• Hoffmann-LA Roche Inc.; USA:2014. US2014/040938A1.
   Google Scholar
• Kaczocha M, Glaser ST, Deutsch DG. Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci. 2009;106:6375–6380.
   PubMed Web of Science ®Google Scholar
• The research foundation of state University of New York; USA:2014. WO2014015276A1.
   Google Scholar
• The University of Chicago; USA:2014. US8748470B2.
   Google Scholar
• The University of Chicago; USA:2014. US2014/0363522A1.
   Google Scholar
• The University of Chicago; USA:2012. US2012/0289570A1.
   Google Scholar
• Feng AJ, Chen DF. Expression of liver fatty acid binding protein in rat nonalcoholic fatty liver. World Chin J Digestol. 2004;12:1373–1375.
   Google Scholar
• Zhao HP, Liang LQ. The dynamic expression of liver fatty acid binding protein in rat nonalcoholic fatty liver. Chin J Exp Tradit Med Form. 2009;15:64–66.
   Google Scholar
• Dong LH, Li H, Wang F. Expression of liver-type fatty acid-binding protein and vascular endothelial growth factor and their correlation in human hepatoceilular carcinoma. J South Med Univ. 2007;27:318–321.
   Google Scholar
• Kamijo-Ikemori A, Sugaya T, Yasuda T, et al. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care. 2011;34:691–696.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Tuncman G, Görgün CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007;447:959–965.
   PubMed Web of Science ®Google Scholar
• Owada Y, Suzuki I, Noda T, et al. Analysis on the phenotype of E-FABP-gene knockout mice. Mol Cell Biochem. 2002;239:83–86.
   PubMed Web of Science ®Google Scholar
• Maeda K, Uysal KT, Makowski L. Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes. 2003;52:300–307.
   PubMed Web of Science ®Google Scholar
• Hertzel AV, Bennaars-Eiden A, Bernlohr DA. Increased lipolysis in transgenic animals overexpressing the epithelial fatty acid binding protein in adipose cells. J Lipid Res. 2002;43:2105–2111.
   PubMed Web of Science ®Google Scholar
• Shaughnessy S, Smith ER, Kodukula S, et al. Adipocyte metabolism in adipocyte fatty acid binding protein knockout mice (aP2-/-) after short-term high-fat feeding: functional compensation by the keratinocyte [correction of keritinocyte] fatty acid binding protein. Diabetes. 2000;49:904–911.
   PubMed Web of Science ®Google Scholar